Saxon Interests Inc. Buys Shares of 9,571 Pfizer Inc. (NYSE:PFE)

Saxon Interests Inc. acquired a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 9,571 shares of the biopharmaceutical company’s stock, valued at approximately $276,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. State Street Corp raised its position in shares of Pfizer by 1.9% in the second quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock valued at $10,534,558,000 after purchasing an additional 5,374,611 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after acquiring an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares in the last quarter. Morgan Stanley grew its position in shares of Pfizer by 0.4% in the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after purchasing an additional 348,628 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Pfizer during the 4th quarter valued at $3,150,472,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 0.1 %

Shares of PFE traded down $0.03 during mid-day trading on Thursday, reaching $27.75. The company’s stock had a trading volume of 39,620,254 shares, compared to its average volume of 43,835,094. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22. The stock has a market cap of $157.14 billion, a PE ratio of 77.08, a P/E/G ratio of 1.24 and a beta of 0.61. The company’s fifty day moving average price is $27.46 and its two-hundred day moving average price is $29.46. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.14 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PFE shares. UBS Group reduced their target price on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a report on Thursday, December 14th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Barclays decreased their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a report on Thursday, December 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Friday, March 1st. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.